Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 431

1.

Cationic membrane-active peptides - anticancer and antifungal activity as well as penetration into human skin.

Do N, Weindl G, Grohmann L, Salwiczek M, Koksch B, Korting HC, Schäfer-Korting M.

Exp Dermatol. 2014 May;23(5):326-31. doi: 10.1111/exd.12384.

PMID:
24661024
2.

Improving topical non-melanoma skin cancer treatment: In vitro efficacy of a novel guanosine-analog phosphonate.

Ali-von Laue C, Zoschke C, Do N, Lehnen D, Küchler S, Mehnert W, Blaschke T, Kramer KD, Plendl J, Weindl G, Korting HC, Hoeller Obrigkeit D, Merk HF, Schäfer-Korting M.

Skin Pharmacol Physiol. 2014;27(4):173. doi: 10.1159/000354118. Epub 2014 Feb 5.

PMID:
24503861
3.

Design, synthesis, inhibition studies, and molecular modeling of pepstatin analogues addressing different secreted aspartic proteinases of Candida albicans.

Cadicamo CD, Mortier J, Wolber G, Hell M, Heinrich IE, Michel D, Semlin L, Berger U, Korting HC, Höltje HD, Koksch B, Borelli C.

Biochem Pharmacol. 2013 Apr 1;85(7):881-7. doi: 10.1016/j.bcp.2012.12.008. Epub 2012 Dec 21.

PMID:
23262278
4.

Glycosylation of Candida albicans cell wall proteins is critical for induction of innate immune responses and apoptosis of epithelial cells.

Wagener J, Weindl G, de Groot PW, de Boer AD, Kaesler S, Thavaraj S, Bader O, Mailänder-Sanchez D, Borelli C, Weig M, Biedermann T, Naglik JR, Korting HC, Schaller M.

PLoS One. 2012;7(11):e50518. doi: 10.1371/journal.pone.0050518. Epub 2012 Nov 30.

5.

Esterase activity in excised and reconstructed human skin--biotransformation of prednicarbate and the model dye fluorescein diacetate.

Bätz FM, Klipper W, Korting HC, Henkler F, Landsiedel R, Luch A, von Fritschen U, Weindl G, Schäfer-Korting M.

Eur J Pharm Biopharm. 2013 Jun;84(2):374-85. doi: 10.1016/j.ejpb.2012.11.008. Epub 2012 Nov 29.

PMID:
23201050
6.

Efficacy of a tyrothricin-containing wound gel in an abrasive wound model for superficial wounds.

Wigger-Alberti W, Stauss-Grabo M, Grigo K, Atiye S, Williams R, Korting HC.

Skin Pharmacol Physiol. 2013;26(1):52-6. doi: 10.1159/000343907. Epub 2012 Nov 24.

PMID:
23183356
7.

Antimicrobial peptides and skin: a paradigm of translational medicine.

Korting HC, Schöllmann C, Stauss-Grabo M, Schäfer-Korting M.

Skin Pharmacol Physiol. 2012;25(6):323-34. doi: 10.1159/000341990. Epub 2012 Sep 8. Review.

8.

A peptide derived from the highly conserved protein GAPDH is involved in tissue protection by different antifungal strategies and epithelial immunomodulation.

Wagener J, Schneider JJ, Baxmann S, Kalbacher H, Borelli C, Nuding S, Küchler R, Wehkamp J, Kaeser MD, Mailänder-Sanchez D, Braunsdorf C, Hube B, Schild L, Forssmann WG, Korting HC, Liepke C, Schaller M.

J Invest Dermatol. 2013 Jan;133(1):144-53. doi: 10.1038/jid.2012.254. Epub 2012 Jul 26.

9.

Impact of age and body site on adult female skin surface pH.

Schreml S, Zeller V, Meier RJ, Korting HC, Behm B, Landthaler M, Babilas P.

Dermatology. 2012;224(1):66-71. doi: 10.1159/000337029. Epub 2012 Mar 20.

PMID:
22433511
10.

Bioavailability, antipsoriatic efficacy and tolerability of a new light cream with mometasone furoate 0.1%.

Korting HC, Schöllmann C, Willers C, Wigger-Alberti W.

Skin Pharmacol Physiol. 2012;25(3):133-41. doi: 10.1159/000335656. Epub 2012 Feb 17.

PMID:
22353786
11.

Reflectance confocal microscopy in the diagnosis of partially and completely amelanotic melanoma: report on seven cases.

Maier T, Sattler EC, Braun-Falco M, Korting HC, Ruzicka T, Berking C.

J Eur Acad Dermatol Venereol. 2013 Jan;27(1):e42-52. doi: 10.1111/j.1468-3083.2012.04465.x. Epub 2012 Feb 10.

PMID:
22324783
12.

Disseminated cutaneous glomangiomas in an adolescent boy.

Borovaya A, Kunte C, Flaig MJ, Albrecht K, Goldscheider I, Korting HC, Ruzicka T, Sárdy M.

Acta Derm Venereol. 2012 May;92(3):324-5. doi: 10.2340/00015555-1281. No abstract available.

13.

Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs.

Elewski BE, Ghannoum MA, Mayser P, Gupta AK, Korting HC, Shouey RJ, Baker DR, Rich PA, Ling M, Hugot S, Damaj B, Nyirady J, Thangavelu K, Notter M, Parneix-Spake A, Sigurgeirsson B.

J Eur Acad Dermatol Venereol. 2013 Mar;27(3):287-94. doi: 10.1111/j.1468-3083.2011.04373.x. Epub 2011 Dec 20.

PMID:
22181693
14.

Host defence against Candida albicans and the role of pattern-recognition receptors.

Gauglitz GG, Callenberg H, Weindl G, Korting HC.

Acta Derm Venereol. 2012 May;92(3):291-8. doi: 10.2340/00015555-1250. Review.

15.

Hallmarks of atopic skin mimicked in vitro by means of a skin disease model based on FLG knock-down.

Küchler S, Henkes D, Eckl KM, Ackermann K, Plendl J, Korting HC, Hennies HC, Schäfer-Korting M.

Altern Lab Anim. 2011 Oct;39(5):471-80.

PMID:
22103940
16.

Efficacy of cream-based novel formulations of hyaluronic acid of different molecular weights in anti-wrinkle treatment.

Pavicic T, Gauglitz GG, Lersch P, Schwach-Abdellaoui K, Malle B, Korting HC, Farwick M.

J Drugs Dermatol. 2011 Sep;10(9):990-1000.

PMID:
22052267
17.

The Munich outbreak of cutaneous cowpox infection: transmission by infected pet rats.

Vogel S, Sárdy M, Glos K, Korting HC, Ruzicka T, Wollenberg A.

Acta Derm Venereol. 2012 Mar;92(2):126-31. doi: 10.2340/00015555-1227.

18.

[Non-pharmacologic management of rosacea].

Borelli C, Korting HC.

Hautarzt. 2011 Nov;62(11):828-33. doi: 10.1007/s00105-011-2145-6. German.

PMID:
22015850
19.

Topical fluticasone propionate: intervention and maintenance treatment options of atopic dermatitis based on a high therapeutic index.

Korting HC, Schöllmann C.

J Eur Acad Dermatol Venereol. 2012 Feb;26(2):133-40. doi: 10.1111/j.1468-3083.2011.04195.x. Epub 2011 Oct 7. Review.

PMID:
21977914
20.

Medical devices in dermatology: topical semi-solid formulations for the treatment of skin diseases.

Korting HC, Schöllmann C.

J Dtsch Dermatol Ges. 2012 Feb;10(2):103-9. doi: 10.1111/j.1610-0387.2011.07764.x. Epub 2011 Aug 18. Review.

21.

Osteopontin expression in plasma of melanoma patients and in melanocytic tumours.

Maier T, Laubender RP, Sturm RA, Klingenstein A, Korting HC, Ruzicka T, Berking C.

J Eur Acad Dermatol Venereol. 2012 Sep;26(9):1084-91. doi: 10.1111/j.1468-3083.2011.04210.x. Epub 2011 Aug 12.

PMID:
21838826
22.

Fifty-kDa hyaluronic acid upregulates some epidermal genes without changing TNF-α expression in reconstituted epidermis.

Farwick M, Gauglitz G, Pavicic T, Köhler T, Wegmann M, Schwach-Abdellaoui K, Malle B, Tarabin V, Schmitz G, Korting HC.

Skin Pharmacol Physiol. 2011;24(4):210-7. doi: 10.1159/000324296. Epub 2011 Mar 11.

PMID:
21412035
23.

Chitin modulates innate immune responses of keratinocytes.

Koller B, Müller-Wiefel AS, Rupec R, Korting HC, Ruzicka T.

PLoS One. 2011 Feb 24;6(2):e16594. doi: 10.1371/journal.pone.0016594.

24.

In vitro models for human skin disease.

Semlin L, Schäfer-Korting M, Borelli C, Korting HC.

Drug Discov Today. 2011 Feb;16(3-4):132-9. doi: 10.1016/j.drudis.2010.12.001. Epub 2010 Dec 10. Review.

PMID:
21146629
25.

Interaction of drug-carrier systems with targets--a study using atomic force microscopy.

Blaschke T, Spangenberg T, Schlupp P, Dathe M, Szcymczak W, Mehnert W, Korting HC, Thalhammer S, Niehus H, Schäfer-Korting M, Kramer KD.

Pharmazie. 2010 Sep;65(9):657-64.

PMID:
21038842
26.

Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies.

Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG.

Mol Med. 2011 Jan-Feb;17(1-2):113-25. doi: 10.2119/molmed.2009.00153. Epub 2010 Oct 5. Review.

27.

[Phytotherapy for skin diseases].

Korting HC.

J Dtsch Dermatol Ges. 2010 Oct;8(10):769-70. doi: 10.1111/j.1610-0387.2010.07538.x. German. No abstract available.

PMID:
20883382
28.

Resistance of liposomal sunscreen formulations against plain water as well as salt water exposure and perspiration.

Korting HC, Schöllmann C.

Skin Pharmacol Physiol. 2011;24(1):36-43. doi: 10.1159/000318229. Epub 2010 Aug 18.

PMID:
20720455
29.

Which plant for which skin disease? Part 2: Dermatophytes, chronic venous insufficiency, photoprotection, actinic keratoses, vitiligo, hair loss, cosmetic indications.

Reuter J, Wölfle U, Korting HC, Schempp C.

J Dtsch Dermatol Ges. 2010 Nov;8(11):866-73. doi: 10.1111/j.1610-0387.2010.07472.x. Review. English, German.

PMID:
20707877
30.
31.

Management of minor acute cutaneous wounds: importance of wound healing in a moist environment.

Korting HC, Schöllmann C, White RJ.

J Eur Acad Dermatol Venereol. 2011 Feb;25(2):130-7. doi: 10.1111/j.1468-3083.2010.03775.x. Epub 2010 Jul 6. Review.

PMID:
20626534
32.

Antitumor effects of guanosine-analog phosphonates identified by molecular modelling.

Schwanke A, Murruzzu C, Zdrazil B, Zuhse R, Natek M, Höltje M, Korting HC, Reissig HU, Höltje HD, Schäfer-Korting M.

Int J Pharm. 2010 Sep 15;397(1-2):9-18. doi: 10.1016/j.ijpharm.2010.06.036. Epub 2010 Jun 25.

PMID:
20600723
33.

Cream or foam in pedal skin care: towards the ideal vehicle for urea used against dry skin.

Borelli C, Bielfeldt S, Borelli S, Schaller M, Korting HC.

Int J Cosmet Sci. 2011 Feb;33(1):37-43. doi: 10.1111/j.1468-2494.2010.00576.x.

PMID:
20572888
34.

Safety and efficacy of sertaconazole nitrate cream 2% in the treatment of tinea pedis interdigitalis: a subgroup analysis.

Borelli C, Korting HC, Bödeker RH, Neumeister C.

Cutis. 2010 Feb;85(2):107-11.

PMID:
20349685
35.

Efficacy and tolerability of pale sulfonated shale oil cream 4% in the treatment of mild to moderate atopic eczema in children: a multicentre, randomized vehicle-controlled trial.

Korting HC, Schöllmann C, Cholcha W, Wolff L; Collaborative Study Group.

J Eur Acad Dermatol Venereol. 2010 Oct;24(10):1176-82. doi: 10.1111/j.1468-3083.2010.03616.x.

PMID:
20236198
36.

Human polymerase alpha inhibitors for skin tumors. Part 2. Modeling, synthesis and influence on normal and transformed keratinocytes of new thymidine and purine derivatives.

Höltje M, Richartz A, Zdrazil B, Schwanke A, Dugovic B, Murruzzu C, Reissig HU, Korting HC, Kleuser B, Höltje HD, Schäfer-Korting M.

J Enzyme Inhib Med Chem. 2010 Apr;25(2):250-65. doi: 10.3109/14756360903059579.

PMID:
20222764
37.

Carriers in the topical treatment of skin disease.

Korting HC, Schäfer-Korting M.

Handb Exp Pharmacol. 2010;(197):435-68. doi: 10.1007/978-3-642-00477-3_15. Review.

PMID:
20217539
38.

Bilateral areolar and periareolar pityriasis versicolor.

Sárdy M, Korting HC, Ruzicka T, Wolff H.

J Dtsch Dermatol Ges. 2010 Aug;8(8):617-8. doi: 10.1111/j.1610-0387.2010.07348.x. Epub 2010 Feb 25. English, German.

PMID:
20202044
39.

[Acne vulgaris. Role of cosmetics].

Korting HC, Borelli C, Schöllmann C.

Hautarzt. 2010 Feb;61(2):126-31. doi: 10.1007/s00105-009-1832-z. German.

PMID:
20107752
40.

[Physical treatment methods for acne. Light, laser, photodynamic therapy and peeling].

Borelli C, Korting HC.

Hautarzt. 2010 Feb;61(2):132-8. doi: 10.1007/s00105-009-1833-y. German.

PMID:
20107751
41.

[Acne vulgaris].

Korting HC, Lehmann P.

Hautarzt. 2010 Feb;61(2):97-8. doi: 10.1007/s00105-010-1918-7. German. No abstract available.

PMID:
20107749
42.

Innovative agents for actinic keratosis and nanocarriers enhancing skin penetration.

Schäfer-Korting M, Höltje M, Korting HC, Höltje HD.

Skin Pharmacol Physiol. 2010;23(1):6-14. doi: 10.1159/000257258. Epub 2010 Jan 14.

PMID:
20090403
43.

The Phenion full-thickness skin model for percutaneous absorption testing.

Ackermann K, Borgia SL, Korting HC, Mewes KR, Schäfer-Korting M.

Skin Pharmacol Physiol. 2010;23(2):105-12. doi: 10.1159/000265681. Epub 2009 Dec 14.

44.

Tinea of glabrous skin.

Seebacher C, Korting HC, Abeck D, Brasch J, Cornely O, Effendy I, Ginter-Hanselmayer G, Haake N, Hamm G, Hipler UC, Hof H, Mayser P, Ruhnke M, Schlacke KH, Tietz HJ.

J Dtsch Dermatol Ges. 2010 Jul;8(7):549-54. doi: 10.1111/j.1610-0387.2009.07259.x. Epub 2009 Oct 12. English, German. No abstract available.

PMID:
19824925
45.

Direct detection of five common dermatophyte species in clinical samples using a rapid and sensitive 24-h PCR-ELISA technique open to protocol transfer.

Beifuss B, Bezold G, Gottlöber P, Borelli C, Wagener J, Schaller M, Korting HC.

Mycoses. 2011 Mar;54(2):137-45. doi: 10.1111/j.1439-0507.2009.01771.x.

PMID:
19793206
46.

Tetracycline actions relevant to rosacea treatment.

Korting HC, Schöllmann C.

Skin Pharmacol Physiol. 2009;22(6):287-94. doi: 10.1159/000235550. Epub 2009 Sep 25. Review.

PMID:
19786821
47.

[Systematic reviews].

Korting HC, Mickus K, Sterry W, Burgdorf W.

J Dtsch Dermatol Ges. 2009 Aug;7(8):661-2. doi: 10.1111/j.1610-0387.2009.07116.x. German. No abstract available.

PMID:
19708951
48.

[Evidence-based cosmetics: concepts and applications in photoaging of the skin and xerosis].

Pavicic T, Steckmeier S, Kerscher M, Korting HC.

Wien Klin Wochenschr. 2009;121(13-14):431-9. doi: 10.1007/s00508-009-1204-9. Review. German.

PMID:
19657604
49.

Rosacea.

Gauwerky K, Klövekorn W, Korting HC, Lehmann P, Meigel EM, Reinel D, Ruzicka T, Schaller M, Schöfer H, Tietze J.

J Dtsch Dermatol Ges. 2009 Nov;7(11):996-1003. doi: 10.1111/j.1610-0387.2009.07119.x. English, German. No abstract available.

PMID:
19650823
50.

Current topical and systemic approaches to treatment of rosacea.

Korting HC, Schöllmann C.

J Eur Acad Dermatol Venereol. 2009 Aug;23(8):876-82. doi: 10.1111/j.1468-3083.2009.03167.x. Review.

PMID:
19508315

Supplemental Content

Loading ...
Support Center